> The FDA cleared BioLineRx to trial anti-cancer vaccine AGI-134 in solid tumors. The action sets BioLineRx up to expand the trial beyond the U.K. and Israel by opening sites in the U.S. in the first half of next year. Release
> eTheRNA immunotherapies opened a new research base in Ghent, Belgium. The site will house the biotech’s enlarged research and preclinical teams. Statement
> Sylentis presented new data from its failed phase 3 dry eye disease trial. The analysis linked siRNA drug tivanisiran to statistically significant improvements in patients with Sjögren's syndrome. Release
> BerGenBio completed enrollment into the second stage of a phase 2 lung cancer trial that is testing AXL inhibitor bemcentinib in combination with Merck’s Keytruda. Statement
> OMass Therapeutics appointed Rosamond Deegan as CEO. Deegan joins OMass from Bicycle Therapeutics, where she served as chief business officer. Release